Leading the way in stroke recovery

Leo Petrossian is the current Chief Executive Officer of Neurolutions, Inc. He is an experienced nanotechnologist searching for challenging opportunities in biotechnology and medical device entre- and intrapreneurship. Previously he co-founded Neural Analytics and is also the CEO of Nile AI, Inc.

Dr. Petrossian earned his MBA from the UCLA Anderson School of Management in 2014 and earned his Ph.D. & MS in Biomolecular Nanotechnology & Solid-State Device Physics as an NSF IGERT fellow at Arizona State University in 2007. He also holds a double B.S. in Electrical Engineering & Biomedical Engineering from California State University, Long Beach.

Kirsten joined Imperative Care in October 2017 as Vice President Strategic Development, and in early 2020 founded the company’s Patient-at-Home initiative, the development program that served as the basis for the creation of Kandu. Previously, she spent a combined nearly 15 years in the Neurovascular Division of Stryker and Boston Scientific, where she held strategic development, planning, marketing, and product management positions. Kirsten holds several patents in the fields of stroke treatment and detection, and she is the author of several peer-reviewed papers in the field of stroke and access to care.

Seth Wilk is the current Chief Innovation Officer of Neurolutions, Inc. He is an experienced bionanotechnologist searching for challenging opportunities in biotechnology and medical device entre- and intrapreneurship. As a scientist, he has more than 100 publications and patents, >$50M in federal grant funding, and has worked on multiple clinical studies and trials.Dr. Wilk earned his Ph.D. & MS in Biomolecular Nanotechnology & Solid-State Device Physics as an NSF IGERT fellow at Arizona State University in 2005. He also holds a B.S. in Electrical Engineering from The College of New Jersey.

Andy Schultz is the Chief Commercial Officer of Neurolutions, Inc. Prior to joining Neurolutions, he was SVP of Revenue and Operations at Candid, a disruptor in the orthodontic clear aligner space. Andy spent nearly 5 years at Candid leading and scaling through periods of high growth and a major DTC to B2B business pivot.

Prior to Candid, Andy held the title of Vice President Customer Experience and Planning at Scotts Miracle-Gro. Over 13 years there he held various leadership roles in sales, operations, strategy and supply chain. Prior to that time, Andy was a First Officer for Northwest Airlink. He served 8 years in the US Navy aboard the USS Enterprise and as a part of the Blue Angels Flight Demonstration Squadron. Andy graduated from Embry-Riddle Aeronautical University.

Javad is a Business Advisor, Corporate Officer, and Senior Executive with an impressive 35-year track record in healthcare leadership. Specializing in imaging, in vitro, and in vivo industries, he has demonstrated unparalleled expertise in Quality Assurance, Regulatory Affairs, and overall operations on a global scale, including North America, Europe, Latin America, and Asia.

His strong business acumen and strategic leadership have been pivotal in navigating organizations through complex business environments worldwide. Javad has worked with companies of all sizes—from startups to Fortune 500s—managing diverse teams and cultures with finesse.

In his role as Senior Vice President of Global Quality Assurance and Regulatory Affairs at Gambro, he not only enhanced quality systems but also played a key role in business strategy, contributing to the company's successful acquisition by Baxter. His extensive experience also includes tenures at Toshiba Medical Systems, Bayer Healthcare, Siemens Healthcare, and NovaSignal, where he was the Chief of Quality Assurance and Regulatory Affairs.

Javad's business-oriented approach extends to product development and operational excellence. He has been instrumental in streamlining processes, reducing product costs, and implementing efficient organizational designs. His leadership has been crucial in driving product development strategies that align with regulatory compliance and market needs.

Nancey Trevanian Tsai, MD is a board certified Sports Medicine Physician, Diplomate of the American Board of Physical Medicine and Rehabilitation. She is a Clinical Professor of Neurosurgery at the Medical University of South Carolina. She is also the Clinician representative for the IEEE Engineering in Medicine and Biology AdCom, an officer of the South Carolina section of the IEEE, as well as a past Chair of the American Council on Exercise, a past Chair of the South Carolina Medical Association Young Physicians Section, a member of the Medical Society of South Carolina. She has a patent for the Blink Reflexometer in Australia and Japan, and the United States. She has also been a member of the USA Field Archery Team in 2010, 2012, and a national coach for USA Archery/Para- archery, whose athletes include national and world champions.

Sean has extensive professional experience ranging from acute clinical practice to healthcare entrepreneurship. Data analysis and commercial viability drive his work, helping demystify intricacies to enhance both healthcare delivery and business operations. His personal mission is to revolutionize healthcare by integrating cutting-edge technology with human-centric care, ensuring accessibility, efficiency, and excellence. His journey has been characterized by a relentless pursuit of innovation and efficiency. He seeks opportunities to serve as an innovation catalyst, working with forward-thinking organizations and individuals to develop solutions that truly make a difference. Through perseverance, creativity, and a priority-driven focus on value, he aspires to lead the next wave of breakthroughs that fundamentally reshape how health is defined, delivered, and experienced.

Eric C. Leuthardt, M.D. is a highly regarded neurosurgeon and professor at Washington University in St. Louis. He holds positions in several departments, including Neurological Surgery, Neuroscience, Biomedical Engineering, Mechanical Engineering, and Material Sciences, and serves as the Chief of the Division of Neurotechnology. Leuthardt is known for his innovative research in the field of neuroprosthetics, neurotechnologies, advanced brain imaging, and neurosurgical devices.

His work has earned him recognition as a pioneer in applied neuroscience and he has over 1800 patents filed with the US Patent and Trademark Office for various medical devices and brain-computer interface technologies. In addition to his academic and research achievements. He is also a successful entrepreneur, having founded eight startup companies. He is an Emmy Award-winning playwright and the author of two fiction novels.

Internationally acclaimed neurologist and researcher, Tudor G. Jovin, MD, is based at Cooper University Hospital in Camden, New Jersey and presides as the Chief and Chairman of Cooper Neurological Institute. Dr. Jovin is an expert in the interventional and non-interventional treatment for the entire spectrum of stroke and cerebrovascular disorders. He was one of the nation's first interventional neurologists, a medical subspecialty that uses minimally invasive technologies applied from within the vessels to diagnose and treat diseases of the arteries and veins of the head, neck, and spine such as acute stroke, carotid stenosis, intracranial aneurysm, and arteriovenous malformations. In addition to his clinical experience, Dr. Jovin is known internationally for his research activities. He has served as principal investigator for several international clinical studies including REVASCAT, a randomized trial of endovascular therapy versus medical therapy for acute stroke within eight hours of symptoms onset conducted in Spain, and DAWN, a multicenter, international, randomized trial of endovascular therapy versus medical therapy in the beyond eight-hour time window. Both studies are considered landmark studies in the development of treatments for acute stroke and have been published in the New England Journal of Medicine. He is a member of the executive or steering committees for several multicenter national and international trials, and has participated as site principal investigator or co-investigator in multiple national and international trials. Additionally, he serves as editorial board member for numerous medical journals. Dr. Jovin has published more than 300 articles in peer-reviewed journals or book chapters. The consequential nature of his research is evidenced by recently published studies that have identified Dr. Jovin as the highest impact author in the neuro-interventional field. Prior to joining Cooper, Dr. Jovin was a professor of neurology and neurosurgery at the University of Pittsburgh School of Medicine and director of the Center for Neuroendovascular Therapy at the University of Pittsburgh Medical Center (UPMC). At UPMC, he also served as the director of UPMC's Stroke Institute, one of the leading centers for stroke care, education, and research in the world.

Lisa Garrett joined Neurolutions in March 2023 and brings over 20 years experience in medical technology companies. Most recently Lisa was the CFO at Cardiva Medical until its acquisition by Haemonetics in 2021. Previously she served as CFO at ForSight Vision5, Inc., a pharmaceutical research company subsequently acquired by Allergan. Prior to ForSight Vision5, Lisa was the CFO at Corventis, Inc., a wearable arrhythmia sensor company acquired by Medtronic in 2014.

Lisa also served in various financial roles at Guidant Corporation, Sybase and Eli Lilly. Lisa currently sits on the board of Channel Medsystems, a medical device company focused on women's health. Lisa earned a B.B.S. in Accounting and an M.B.A from Indiana University.